NCT02555735
Exceptional Responders With Solid Tumor Cancer to Chemotherapy
Enrolling by Invitation
Not specifiedAges 18+ObservationalAdera Labs, LLC
~250 participants
Updated 2023-02-01 on ClinicalTrials.gov
What's tested:Standard of Care Chemotherapy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identify exceptional responders with cancer to standard of care chemotherapy
Measured over 9 years
Conditions
NCT02555735
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The Pancreatic Cancer Treatment Center of Los Angeles
Los Angeles, Californiano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Brian McCarthy, PhD · STUDY_DIRECTOR · Adera Labs
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histological or cytological confirmation of solid tumor carcinoma.
Patient is treatment-naïve or currently receiving chemotherapy.
ECOG performance status (any).
Exclusion
HIV positive on antiretroviral therapy
Pregnant or lactating
Prior organ allograft
Any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment
What this trial measures
- Identify exceptional responders with cancer to standard of care chemotherapy9 years
Identify responders and non-responders